Cardiovascular disease (CVD) is the main cause of death and disability among people with type 2 diabetes.[2] Adults with type 2 diabetes are two to four times more likely to develop CVD than adults without diabetes.[3] The FDA's decision on semaglutide is based on results from the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which examined the cardiovascular safety of adding Ozempic or placebo to standard-of-care in adults with type 2 diabetes and established cardiovascular disease

Key outcomes (surgery vs GLP-1 medicines alone) Compared to medications, surgery offers: 32% lower risk of death (all-cause mortality) 35% lower risk of major cardiovascular events (heart attack, heart failure, stroke) 47% lower risk of serious kidney disease 54% lower risk of diabetes-related eye damage (retinopathy) Greater average 10-year weight loss: ~21.6% vs ~6.8% Bigger A1c reduction: 0.86% vs 0.23% Why Surgery Outperformed GLP-1s in the Real World Adherence: Whether or not youre in a study, if you have weight loss surgery, you are left with a permanent tool to help you lose weight and maintain that loss, providing you follow some basic rules
Current protocols at specialized clinics typically prescribe subcutaneous doses in the range of 500 mcg to 1 mg per day, administered for 15 to 30 days per cycle
This complex is bonded with copper ions
When appropriate (i.e., with at least 10 studies in a forest plot), publication bias was evaluated using funnel plots in the same software [21,22]